目的:荟萃分析方法评价5-羟色胺(5-HT)1A受体部分激动剂治疗功能性消化不良(FD)的临床疗效及安全性。方法:计算机检索PubMed、Web of Science、CNKI等数据库建库起公开发表的5-HT1A受体部分激动剂治疗FD的随机对照研究(RCT)。RevMan 5....目的:荟萃分析方法评价5-羟色胺(5-HT)1A受体部分激动剂治疗功能性消化不良(FD)的临床疗效及安全性。方法:计算机检索PubMed、Web of Science、CNKI等数据库建库起公开发表的5-HT1A受体部分激动剂治疗FD的随机对照研究(RCT)。RevMan 5.4软件对纳入的资料荟萃分析,并进行亚组分析、分层分析,评价5-HT1A受体部分激动剂对FD的疗效及安全性。结果:纳入19项RCT,共计1575例患者(治疗组801例,对照组774例)。荟萃分析显示:治疗组总有效率高于对照组(OR=4.18,95%CI:3.05~5.73,P<0.00001),而消化道症状评分(SMD=-1.30,95%CI:-1.95~-0.64,P=0.0001)、焦虑状态评分(SMD=-1.22,95%CI:-1.79~-0.65,P<0.0001)和抑郁状态评分(SMD=-1.52,95%CI:-2.41~-0.63,P=0.0008)均低于对照组,嗜睡(OR=4.78,95%CI:1.80~12.70,P<0.05)、口干(OR=3.07,95%CI:1.31~7.19,P<0.05)发生率均高于对照组。结论:与常规或安慰剂治疗相比,联合应用5-HT1A受体部分激动剂能提高总体疗效,但嗜睡及口干发生率较高。展开更多
A series of 3-（4-arylpiperazin-1-yl）-1-（benzo[b]thiophen-3-yl）-2-methylpropanol derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies.The synthesized compounds were evaluated for t...A series of 3-（4-arylpiperazin-1-yl）-1-（benzo[b]thiophen-3-yl）-2-methylpropanol derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies.The synthesized compounds were evaluated for their dual 5-HT1A/5-HTT activities.展开更多
5-HT1A receptor is a crucial therapeutic target for the treatment of anxiety, depression, pain, etc. Design and preparation of potent 5-HT1A receptor ligands for drug discovery has attracted extensive attention in the...5-HT1A receptor is a crucial therapeutic target for the treatment of anxiety, depression, pain, etc. Design and preparation of potent 5-HT1A receptor ligands for drug discovery has attracted extensive attention in the past few years. In this paper, a three dimensional model of human 5-HT1A receptor was constructed by means of homology modeling. And the docking of MP349 to the receptor suggested a reliable binding mode for 5-HT1A receptor ligand. Based on this ligand-receptor binding mode, an elaborate receptor structure based pharmacophore model was established, which revealed many important features responsible for ligand and 5-HT1A receptor interactions. A virtual screening experiment verified the ability of this pharmacophore model to discover true 5-HT1A receptor ligand. The results of this research would provide important information for further optimizations of 5-HT1A receptor ligands and guide related new lead discoveries.展开更多
文摘目的:荟萃分析方法评价5-羟色胺(5-HT)1A受体部分激动剂治疗功能性消化不良(FD)的临床疗效及安全性。方法:计算机检索PubMed、Web of Science、CNKI等数据库建库起公开发表的5-HT1A受体部分激动剂治疗FD的随机对照研究(RCT)。RevMan 5.4软件对纳入的资料荟萃分析,并进行亚组分析、分层分析,评价5-HT1A受体部分激动剂对FD的疗效及安全性。结果:纳入19项RCT,共计1575例患者(治疗组801例,对照组774例)。荟萃分析显示:治疗组总有效率高于对照组(OR=4.18,95%CI:3.05~5.73,P<0.00001),而消化道症状评分(SMD=-1.30,95%CI:-1.95~-0.64,P=0.0001)、焦虑状态评分(SMD=-1.22,95%CI:-1.79~-0.65,P<0.0001)和抑郁状态评分(SMD=-1.52,95%CI:-2.41~-0.63,P=0.0008)均低于对照组,嗜睡(OR=4.78,95%CI:1.80~12.70,P<0.05)、口干(OR=3.07,95%CI:1.31~7.19,P<0.05)发生率均高于对照组。结论:与常规或安慰剂治疗相比,联合应用5-HT1A受体部分激动剂能提高总体疗效,但嗜睡及口干发生率较高。
基金supported by the National Natural Science Foundation of China(No.20576094).
文摘A series of 3-（4-arylpiperazin-1-yl）-1-（benzo[b]thiophen-3-yl）-2-methylpropanol derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies.The synthesized compounds were evaluated for their dual 5-HT1A/5-HTT activities.
文摘5-HT1A receptor is a crucial therapeutic target for the treatment of anxiety, depression, pain, etc. Design and preparation of potent 5-HT1A receptor ligands for drug discovery has attracted extensive attention in the past few years. In this paper, a three dimensional model of human 5-HT1A receptor was constructed by means of homology modeling. And the docking of MP349 to the receptor suggested a reliable binding mode for 5-HT1A receptor ligand. Based on this ligand-receptor binding mode, an elaborate receptor structure based pharmacophore model was established, which revealed many important features responsible for ligand and 5-HT1A receptor interactions. A virtual screening experiment verified the ability of this pharmacophore model to discover true 5-HT1A receptor ligand. The results of this research would provide important information for further optimizations of 5-HT1A receptor ligands and guide related new lead discoveries.
